Compare iShares Russell 2000 ETF (IWM) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs Pfizer Inc — how do they compare? iShares Russell 2000 ETF trades at $278.7 (market cap $78.56B), while Pfizer Inc trades at $27.74 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 2× iShares Russell 2000 ETF's market cap, and Pfizer Inc pays a 6.14% dividend while iShares Russell 2000 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and Pfizer Inc for 158 Days on average.
| IWM | PFE | |
|---|---|---|
Market Cap | $78.56B | $159.59B |
Volume | 24,585,463 | 30,937,010 |
52-Week High | $305.06 | $29.02 |
52-Week Low | $229.13 | $23.67 |
Typical Hold Time | 83 Days | 158 Days |
Sector | — | Health |
Enterprise Value | — | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM trades at $277.72, down 1.27% with bearish technical signals from moving averages and key indicators. The ETF faces headwinds from Federal Reserve rate hikes and underperformance relative to large-cap indices. Recent news highlights IWM's decade-long trailing of the S&P 500 while carrying higher risk, with institutional selling pressure emerging.
The outlook remains challenging as small-caps face tightening financial conditions and energy price pressures. Investment opportunity exists for long-term value investors seeking diversification from tech-heavy large-caps, though near-term risks include continued Fed hawkishness and weak small-cap breadth in the current market environment.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
